mybacs - NOAH19 Berlin
•
1 like•164 views
Revolutionary Consumer Products: Company presentation by Carl-Philipp von Polheim, mybacs at the NOAH Conference Berlin 2019, 13-14 June, STATION.
Recommended
Recommended
More Related Content
Similar to mybacs - NOAH19 Berlin
Similar to mybacs - NOAH19 Berlin (20)
More from NOAH Advisors
More from NOAH Advisors (20)
Recently uploaded
Recently uploaded (20)
mybacs - NOAH19 Berlin
- 1. @
- 2. @NOAHConference @noah_conference @noah-conference @NOAHConference FOLLOW USONSOCIAL
- 4. Who suffered from digestion issues when travelling abroad?
- 5. 80 million travelers are affected by travelers diarrhea (TD) each year
- 6. Why do only travelers and not locals suffer from TD?
- 7. Because their gut has not adapted to the foodborne bacteria it is facing
- 8. Diarrhea remains to be a major problem to individuals in various situations 55% of people traveling to developing countries are affected Highest risk regions are Africa, the Middle East, South Asia & Latin America Food and water contaminated with fecal matter is the main reservoir for pathogens The major pathogen in TD are bacteria. These however, vary strongly between geographic regions - Strictly Confidential -
- 9. • Only offering symptomatic treatment • Narrow therapeutic window, resulting in constipation when overdosed • Multiple recorded side effects • Should not be used without medical supervision • Result in resistant bacteria if used too frequently Synbiotics • No recorded side effects • Repopulate the healthy intestinal microbiome • Acts preventively • Causal instead of symptomatic treatment Opioids Antibiotics No drugs address diarrhea treatment with regard to its specific cause - Strictly Confidential -
- 10. mybacs uses the unique pathogenic profile of high risk travel regions to offer specific treatment Geographically specific treatment Very safe, classified as a food supplement Unique & intuitive packaging - Strictly Confidential -
- 11. The perfect match for every region - Strictly Confidential -
- 12. mybacs targets 5 verticals within the microbiome sphere Daily well-beingTravel Dietary change Smoking Antibiotics ü Launched in February 2019 Projected launch Q3 2019 Projected launch Q1 2020 Projected launch Q3 2020 Projected launch Q1 2021
- 13. Meet the Founders Sebastian Wahl Founder & Co-CEO • M.Sc. with distinction in Medicinal and Industrial Pharmaceutical Sciences from ETH Zurich • Scientist at FOG Pharmaceuticals developing a new cancer treatment • Work experience in Venture Capital and Strategy Consulting Carl-Philipp von Polheim Founder & Co-CEO • M.Sc. with distinction in Management from ESCP Europe • Worked as an Investment Banking Analyst in the technology sector with a focus on corporate financing and M&A • Work experience in Startups and Private Equity - Strictly Confidential -
- 14. Status quo o 2 offices in Zug and Munich o CHF 240k in funding from Angels Funding & Financials Partnerships Company Market o Founded in August 2018, launched in February 2019 o 6 Team members in the fields of Pharma & Business o Current monthly run-rate: € 10.000 (3 months post launch) o +1000 Travelbacs sold o Probiotics Global: $ 32bn o Probiotics Europe: $ 12bn o CAGRs: 7– 9 %
- 15. Thank You – Let’s get in touch - Strictly Confidential - Sebastian Wahl Fon: +49 152 226 900 30 Email: sebastian@mybacs.co Carl-Philipp von Polheim Fon: +49 173 362 76 19 Email: carl@mybacs.co Zugerstrasse 76B 6340 Baar mybacs.co